Glutathione: oral, IV and nasal, and what the trials found for each

Glutathione is a tripeptide: three amino acids, glutamate, cysteine and glycine, joined together. Almost every cell makes it, and inside cells it sits at millimolar concentrations, far above most other small antioxidants ^[1].

One structural detail matters for everything that follows. The bond between glutamate and cysteine is a gamma-peptide bond rather than the usual alpha bond, which protects glutathione from most protein-digesting enzymes but not from gamma-glutamyl transpeptidase, an enzyme on cell surfaces that breaks it down outside cells ^[1]. That is the root of the oral absorption problem in § 03.

Inside the cell glutathione switches between two forms. Reduced glutathione (GSH) carries a free thiol group that can donate electrons. Oxidized glutathione (GSSG) is two GSH molecules joined by a disulfide bond, which is what GSH becomes after it has neutralized an oxidant. The GSH-to-GSSG ratio is one of the standard measures of a cell's redox state; healthy cells keep it heavily on the reduced side ^[1].

Four jobs, roughly.

Direct scavenging. GSH donates electrons to reactive oxygen and nitrogen species and becomes GSSG; glutathione reductase then recycles it using NADPH ^[1].

Enzyme cofactor. Glutathione peroxidases need GSH to break down hydrogen peroxide and lipid hydroperoxides ^[1].

Detoxification. Glutathione S-transferases attach GSH to reactive compounds, including the toxic metabolite of acetaminophen, so the body can excrete them ^[1].

Pigment. Glutathione inhibits tyrosinase, the enzyme that starts melanin production, and shifts output from dark eumelanin toward lighter pheomelanin ^[9]. This one mechanism is what the skin-lightening market is built on. Whether any supplement route gets enough glutathione into skin pigment cells to matter is a separate question, and § 06 covers the trials.

The body makes glutathione in two steps inside the cell, and cysteine supply is the usual limit on how fast ^[1]. That is why cysteine donors such as N-acetylcysteine are the common way to raise cellular glutathione.

In 1992 researchers gave seven healthy volunteers a single oral dose of glutathione and measured plasma levels for four and a half hours. Glutathione, cysteine and glutamate in plasma did not rise significantly, and the authors concluded that the systemic availability of a single oral dose is negligible, because the molecule is broken down in the gut first ^[2].

That is the baseline every other form is sold against. Long-term daily oral dosing, liposomal and micellar capsules, lozenges held under the tongue, IV infusions and nasal sprays are all attempts to get around it. IV skips the gut but meets the same enzymes in the bloodstream, so a high blood level after an infusion does not show that the molecule reached the cells that matter.

When a clinic cites a study showing that glutathione does something, the first question is which route the study used.

Skin lightening. The one placebo-controlled trial of IV glutathione for skin tone was run at a dermatology department in Multan, Pakistan, and published in 2016 ^[7]. Women received an injection product containing 1,200 mg of glutathione with vitamin C and collagen, twice a week for six weeks; the control group received saline. Of 50 enrolled, 32 finished. Six of 16 on glutathione (37.5%) improved against 3 of 16 on placebo (18.7%), a difference that was not statistically significant (p = 0.054).

By six months after treatment only one patient kept the improvement. The authors reported adverse effects in all subjects and stopped treatment in eight for abnormal liver tests and in one for anaphylactic shock ^[7]. Their conclusion: glutathione is not very effective for lightening skin, and side effects are common.

The Philippines FDA, in a market where IV skin lightening is widespread, warned the public in 2019 that no injectable product is approved there for skin lightening, noting reported toxic effects on the liver, kidneys and nervous system and the possibility of Stevens-Johnson syndrome. Injectable glutathione is approved in the Philippines only as an adjunct to cisplatin chemotherapy ^[19].

Parkinson's disease. Glutathione is depleted early in the part of the brain Parkinson's damages, which made IV glutathione a reasonable thing to test. A randomized, double-blind pilot gave 1,400 mg IV three times a week for four weeks to 11 patients and placebo to 10. It was well tolerated, and motor scores did not differ significantly from placebo ^[10].

Chemotherapy neuropathy. Glutathione has been tried to prevent nerve damage from platinum chemotherapy. The American Society of Clinical Oncology's 2020 guideline concluded that no agent is recommended for preventing chemotherapy-induced neuropathy ^[14].

What the FDA has said. In February 2019 the FDA warned compounders not to use a supplier's glutathione powder for sterile injectables. Seven patients at one clinic had reacted within minutes of an IV dose with nausea, vomiting, chills and lightheadedness; one, with low blood pressure and difficulty breathing, was taken to hospital. A second patient elsewhere was admitted with chills, fever and shaking. The agency linked the reactions to potentially high levels of endotoxin and published the details on June 7, 2019 ^[15].

On August 27, 2026 it issued a new alert: at least 30 patients had adverse events after IV glutathione compounded by different pharmacies from one lot of dietary-supplement-grade glutathione, with fever, chills, signs of shock and sepsis-like symptoms, some needing hospital care. Two Texas pharmacies recalled their glutathione injectables for elevated endotoxin, and the FDA said it was still receiving reports ^[16].

The CDC, investigating with state health departments since Texas reported a cluster at a wellness clinic in July 2026, counted more than 25 people sick in at least four states (Texas, Washington, Florida and New York) by September 11, 2026. At least three were hospitalized, all after IV doses, and one needed intensive care for shock and abnormal blood clotting ^[20].

On October 1, 2026 a third Texas pharmacy, Greenwich Rx, recalled lots of its compounded glutathione for possible elevated endotoxin after two patients needed emergency care following IV doses ^[21]. These alerts are about the raw material and sterility rather than glutathione's own pharmacology, and they make the same point: a supplement-grade ingredient is not fit to inject.

Intramuscular glutathione is sold mainly for skin lightening, and the controlled human evidence for it is effectively absent: we found no randomized trial of intramuscular glutathione for any indication. The Philippines FDA warning in § 04 covers injectable glutathione for skin lightening as a whole ^[19]. It carries the risks of any injectable compounded product, including the sourcing problem behind the FDA alerts: in the 2026 outbreak the CDC counted patients who had received glutathione into a muscle or under the skin as well as into a vein ^[20].

Standard capsules, taken daily. The best human trial of glutathione by any route is a six-month randomized, double-blind, placebo-controlled study of 54 non-smoking adults, published in 2015 ^[3]. Participants took 250 mg or 1,000 mg a day or placebo.

At six months the high dose had raised glutathione by 30 to 35% in red blood cells, plasma and lymphocytes and by 260% in cells scraped from the inside of the cheek; the low dose raised it by 17% in whole blood and 29% in red blood cells. Natural killer cell activity more than doubled against placebo at three months on the high dose. Levels returned to baseline within a month of stopping ^[3].

So daily oral dosing does raise body stores, unlike the single dose in § 03. What the trial measured were biomarkers in healthy people over six months. It did not test whether anyone got healthier.

Liposomal and micellar capsules. A one-month pilot of liposomal glutathione at 500 or 1,000 mg a day in 12 healthy adults reported increases of up to 40% in whole blood and 100% in immune cells ^[4]. A 2026 crossover pilot in 14 adults found that a micellar formulation (LipoMicel) gave about 2.5 times the increase in blood glutathione of a standard capsule after a single dose ^[5]. Both are small, short and about absorption, not outcomes.

Under the tongue. A randomized, double-blind crossover trial in 16 men with cardiovascular risk factors tested a sublingual glutathione. Total and LDL cholesterol fell compared with placebo; blood-vessel function and oxidative stress markers did not change overall ^[6]. A small signal, not grounds for a recommendation.

Skin. A 2019 systematic review found four small studies of glutathione for skin colour, three of them placebo-controlled. Oral glutathione at 500 mg a day lightened sun-exposed skin on a melanin index, with no effect on skin that is not exposed to sun. The authors called the evidence inconclusive because of study quality and inconsistent results, and reported only non-serious adverse events ^[8].

Nasal delivery is where Parkinson's research went after IV. In a study of 15 people with mid-stage Parkinson's, a single 200 mg nasal dose raised glutathione in the brain, measured by magnetic resonance spectroscopy, and the rise lasted at least an hour ^[11]. That was the first evidence that nasal glutathione reaches the brain.

The follow-up was a randomized, double-blind phase IIb trial in 45 patients: placebo, 100 mg or 200 mg three times a day for three months. Every group improved, including placebo, and neither glutathione dose did better than placebo. One patient on the high dose developed cardiomyopathy ^[12]. The authors concluded the results did not show nasal glutathione beats placebo over three months and that longer, larger trials would be needed.

So nasal glutathione reaches the brain, and in the one controlled efficacy trial it did no better than saline.

The risk depends heavily on the route.

Oral was well tolerated at 1,000 mg a day for six months in the main trial ^[3], and the skin review found only non-serious adverse events ^[8].

IV is where the serious events cluster: liver-test abnormalities and anaphylaxis in the skin trial ^[7], and endotoxin reactions requiring hospital care in both FDA alerts and the 2026 CDC investigation ^[15][16][20]. Nothing about IV glutathione in a wellness setting is standardized: there is no FDA-approved product, and ingredient grade, dose and sterility vary by pharmacy.

Nasal has the smallest safety record because its trials are small; one case of cardiomyopathy was reported in the phase IIb trial ^[12].

Inhaled glutathione can tighten the airways in asthma. In a randomized crossover study of eight people with mild asthma, nebulized glutathione caused marked bronchoconstriction, cough and breathlessness, which a bronchodilator taken beforehand prevented ^[13].

Pigment. If glutathione reaches pigment cells in meaningful amounts it reduces melanin ^[9]. In the skin-lightening market that is the selling point; for anyone using glutathione for something else it is an effect nobody has studied over the long term.

• People with asthma, especially with any inhaled or sprayed product ^[13].
• Anyone on platinum chemotherapy. Glutathione is used as an adjunct to cisplatin in some countries ^[19], and the possibility that it interferes with chemotherapy has not been ruled out. This is a decision for the oncologist.
• People with liver problems, given the liver-test abnormalities in the IV skin trial ^[7].
• Pregnancy and breastfeeding: no trials.
• Anyone considering IV or intramuscular glutathione: ask the clinic which pharmacy compounded it and whether the glutathione is pharmaceutical grade, which is the question the FDA alerts turn on ^[15][16].

Oral glutathione is sold in the US as a dietary supplement. No oral glutathione product is approved by the FDA as a drug.

Injectable glutathione has no FDA-approved product either. What clinics use is compounded. Glutathione is in Category 1, "under evaluation", of the FDA's list of bulk drug substances nominated for compounding under section 503A (list updated May 14, 2026) ^[17], and in Category 1 of the equivalent list for outsourcing facilities under section 503B (updated March 21, 2025) ^[18].

Category 1 means the FDA has not yet decided whether to add it to the final lists, and under its interim policies it generally does not object to compounding with it in the meantime, subject to the other conditions of those policies ^[17][18]. Those conditions include using an ingredient appropriate for injection, which is exactly what both FDA alerts were about ^[15][16].

This page does not name sellers or compare their prices; the judgements here are clinical ones. PeptidesToGo publishes that side: which telehealth sellers carry compounded glutathione, by injection or nasal spray, what each charges and the date each price was read. Whichever you look at, the question from the alerts above still applies: which pharmacy compounds it, and from what grade of ingredient.

Elsewhere, the Philippines FDA has approved injectable glutathione only as an adjunct to cisplatin chemotherapy and warns against injecting it for skin lightening ^[19].

What is solid: glutathione is the cell's main small-molecule antioxidant, a single oral dose barely reaches the blood, and daily oral dosing for months raises glutathione in blood and cells.

What is unproven: any health benefit from raising it in people who are not deficient. The controlled trials of IV glutathione in Parkinson's and of nasal glutathione in Parkinson's both found no difference from placebo, and the IV skin-lightening trial missed significance while producing serious adverse events.

What is concerning: IV glutathione from compounding pharmacies, where the FDA has twice traced clusters of reactions to supplement-grade raw material, most recently in an outbreak the CDC was still investigating in September 2026, with a further pharmacy recall on October 1 ^[16][20][21].

For anyone considering glutathione, oral at the doses in the six-month trial is the best-studied and best-tolerated option, and the realistic expectation is a change in blood levels rather than a change you can feel.

Counted from PubMed and ClinicalTrials.gov on October 9, 2026. A study counts only if participants were given glutathione. How we count, and the same figures for every peptide we cover.

Most recent published trials

• Formulation-dependent differences in systemic glutathione availability: Comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults. Eur J Pharm Biopharm, 2026.
• Efficacy and safety of injectable sodium hyaluronate with vitamin C, tranexamic acid, and glutathione for pigmented dark circles. J Dermatolog Treat, 2025.
• Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial. Acta Dermatovenerol Alp Pannonica Adriat, 2025.
• Glutathione, Vitamin C, and Cysteine Use in Autistic Children With Disruptive Behavior: A Double-Blind, Placebo-Controlled Crossover Pilot Study. J Dev Behav Pediatr, 2025.
• Noninvasive high-intensity focused ultrasound for skin brightening efficacy using a topical agent containing glutathione and hyaluronic acid. J Dermatolog Treat, 2024.

Most recent registrations

• S-Acetyl Glutathione and Performance Recovery in Soccer NCT07690124, not yet recruiting, planned start 2026.
• Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma NCT07448415, not yet recruiting, planned start 2026.
• Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet NCT07379216, recruiting, started 2026.
• Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Vitamin C and Glutathione Liquid Sachet NCT07302828, completed, started 2025.
• The Impact of Qualia Gluthathione+ on Blood Glutathione Levels NCT07221955, completed, started 2025.

A registration is a plan filed before a study starts, not a result.